NYSE · Diagnostics & Research · USD
Waters Corporation (WAT) Stock Analysis
Waters Corporation (WAT) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
WAT Key Statistics
As of Oct 21, 2026Trading
- Open
- $436.90
- Previous Close
- $442.83
- Day's Range
- 435.07–459.62
- 52-Week Range
- 282.77–459.62
- Volume
- 952.39K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.15
Valuation
- Market Cap
- $44.92B
- P/E Ratio
- 115.82
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 27.68
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 1.65
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 9.67
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 3.95
Financials (FY)
- Revenue (FY)
- $3.17B+6.99%
- Net Income (FY)
- $642.63M+0.75%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 3.59%
- Shares Outstanding
- 98.19M
- 1-Year Return
- +30.99%
Dividend and dates
- Earnings Date
- November 3, 2026
- Avg Volume
- 801.68K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, WAT closed at $457.47, +30.99% over 1 year.
Waters Corporation (WAT) has a market capitalization of $44.92B.
In fiscal 2025, WAT reported revenue of $3.17B.
WAT Stock Return by Calendar Year
Waters Corporation (WAT) 10-year return: what $10,000 became
- 1 year
- $10,000 $13,099
- +30.99%
- 5 years
- $10,000 $12,672
- +26.72%
- 10 years
- $10,000 $29,291
- +192.91%
If you had invested $10,000 in Waters Corporation (WAT) 10 years ago, at the close on October 21, 2016, it would have been worth $29,291 at the close on October 21, 2026: +192.91% in total, +11.35% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +20.44% |
| 2025 | +2.39% |
| 2024 | +12.68% |
| 2023 | −3.90% |
| 2022 | −8.06% |
| 2021 | +50.59% |
| 2020 | +5.89% |
| 2019 | +23.85% |
| 2018 | −2.35% |
| 2017 | +43.75% |
| 2016 (partial year) | −14.61% |
As of October 21, 2026.
WAT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $3.17B | $642.63M | 20.3% |
| 2024 | $2.96B | $637.83M | 21.6% |
| 2023 | $2.96B | $642.23M | 21.7% |
| 2022 | $2.97B | $707.76M | 23.8% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $3.17B | $1.88B | $802.59M | $642.63M | 20.3% |
| 2024 | $2.96B | $1.76B | $837.92M | $637.83M | 21.6% |
| 2023 | $2.96B | $1.76B | $817.68M | $642.23M | 21.7% |
| 2022 | $2.97B | $1.72B | $883.19M | $707.76M | 23.8% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
WAT Valuation vs Diagnostics & Research Median
Median of 45 stocks| Metric | WAT | Diagnostics & Research median | vs median |
|---|---|---|---|
| P/E | 115.82 | 37.59 | 3.1x the median |
| P/S ratio | 9.67 | 5.23 | 85% above |
| Profit margin | 3.59% | −0.93% | 4.5 pts above |
Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Waters (WAT) Stock Looks 26% Overvalued On Cash Flow Estimates
YahooWaters Launches AI Link to Advance AI-Enabled LC-MS Workflows
YahooJosh Brown's "Best Stocks in the Market:" Waters and Thermo Fisher
CNBCWaters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option
YahooEarnings Preview: What to Expect From Waters Corporation’s Report
BarchartUltima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation
Yahoo
All 20 articles ↓Show fewer ↑
Here’s How Much You Would Have Made Owning Waters Stock In The Last 20 Years
BenzingaWaters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
YahooWaters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
YahooTD Cowen Maintains Buy on Waters, Raises Price Target to $515
BenzingaHere's Why You Should Retain WAT Stock in Your Portfolio for Now
YahooBarclays Maintains Overweight on Waters, Raises Price Target to $500
BenzingaCellCarta, Waters Corporation collaborate on companion diagnostics
medicaldevice-network.comCellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development
YahooWaters Corporation Schedules Third Quarter 2026 Earnings Conference Call
YahooGuggenheim Maintains Buy on Waters, Raises Price Target to $490
BenzingaIf You Invested $1000 In Waters Stock 20 Years Ago, You Would Have This Much Today
BenzingaThe Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push
YahooWaters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
MarketBeatWaters: Positive Momentum Rides High Again
SeekingAlpha
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Diagnostics & Research Stocks
Thermo Fisher Scientific Inc.
$256.61B
DHRDanaher Corporation
$164.40B
NTRANatera, Inc.
$59.59B
AAgilent Technologies, Inc.
$50.12B
IQVIQVIA Holdings Inc.
$45.53B
IDXXIDEXX Laboratories, Inc.
$43.60B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B













